Clinical trials in Poitiers – page 23

623 clinical trials in Poitiers, France across 1 research site. Every trial is listed in the EU Clinical Trials Register and updated daily.

Our site in FranceEssaisCliniques.fr

Poitiers at a glance

623

clinical trials

Research sites1

Quick filters

623 trials in Poitiers

Open in trial search

Bronchopulmonary aspergillosis

Recruiting

Study Comparing Itraconazole and Nebulised Amphotericin B with Itraconazole Alone for Patients with Chronic Pulmonary Aspergillosis

Registered drugNo placebo

Study Comparing Itraconazole and Nebulised Amphotericin B with Itraconazole Alone for Patients with Chronic Pulmonary Aspergillosis

Registered drugNo placebo

France

Participants:18–64 years · 65+ years
Substances:Itraconazole
Sponsor:Centre Hospitalier Universitaire De Poitiers

Contact Research Centre

Triple negative breast cancer

Recruiting

Study of Sacituzumab Govitecan and Pembrolizumab for Patients with Triple Negative Breast Cancer with Residual Disease After Surgery and Therapy

Registered drugNo placebo

Study of Sacituzumab Govitecan and Pembrolizumab for Patients with Triple Negative Breast Cancer with Residual Disease After Surgery and Therapy

Registered drugNo placebo

France

Participants:18–64 years · 65+ years
Substances:Capecitabine
Sponsor:Gilead Sciences Inc.

Contact Research Centre

Cerebral haemorrhage

Recruiting

Study on Avoiding Anticoagulation with Apixaban for Patients with Intracerebral Hemorrhage

Registered drugNo placebo

Study on Avoiding Anticoagulation with Apixaban for Patients with Intracerebral Hemorrhage

Registered drugNo placebo

France

Participants:18–64 years · 65+ years
Substances:Apixaban
Sponsor:Centre Hospitalier Universitaire De Lille

Contact Research Centre

Acute lymphocytic leukaemia+1

Recruiting

Study on Blinatumomab, Ponatinib, and Isatuximab for Adults Aged 18-65 with Newly Diagnosed Acute Lymphoblastic Leukemia or T-Cell Lymphoblastic Lymphoma

Registered drugNo placebo

Study on Blinatumomab, Ponatinib, and Isatuximab for Adults Aged 18-65 with Newly Diagnosed Acute Lymphoblastic Leukemia or T-Cell Lymphoblastic Lymphoma

Registered drugNo placebo

France

Participants:18–64 years · 65+ years
Substances:Blinatumomab
Sponsor:Assistance Publique Hopitaux De Paris

Contact Research Centre

Neoplasm

Recruiting

Study on the Safety and Effectiveness of ART0380 Alone or with Gemcitabine or Irinotecan for Patients with Advanced or Metastatic Solid Tumors

Registered drugNo placebo

Study on the Safety and Effectiveness of ART0380 Alone or with Gemcitabine or Irinotecan for Patients with Advanced or Metastatic Solid Tumors

Registered drugNo placebo

France

Participants:18–64 years · 65+ years
Substances:ART0380 mesilate
Sponsor:Artios Pharma Limited

Contact Research Centre

Dermatitis atopic

Not yet recruiting

Efficacy and Safety of Lebrikizumab in Adults and Adolescents with Moderate-to-Severe Face and Neck Atopic Dermatitis

Registered drug

Efficacy and Safety of Lebrikizumab in Adults and Adolescents with Moderate-to-Severe Face and Neck Atopic Dermatitis

Registered drug

France

Participants:0–17 years · 18–64 years · 65+ years
Substances:Lebrikizumab
Sponsor:Almirall S.A.

Contact Research Centre

Parkinson's disease

Not yet recruiting

A study to test if BHV-8000 is effective and safe for adults with early Parkinson's disease

Registered drug

A study to test if BHV-8000 is effective and safe for adults with early Parkinson's disease

Registered drug

France

Participants:18–64 years · 65+ years
Substances:Ioflupane (123I)
Sponsor:Biohaven Therapeutics Ltd.

Contact Research Centre

VEXAS syndrome

Not yet recruiting

A Randomized, Double‑Blind, Placebo‑Controlled Study of Momelotinib Dihydrochloride Monohydrate in Patients with VEXAS Syndrome

Investigational

A Randomized, Double‑Blind, Placebo‑Controlled Study of Momelotinib Dihydrochloride Monohydrate in Patients with VEXAS Syndrome

Investigational

France

Participants:18–64 years · 65+ years
Substances:Momelotinib Dihydrochloride Monohydrate
Sponsor:Glaxosmithkline Research & Development Limited

Contact Research Centre

Chronic lymphocytic leukaemia+1

Not yet recruiting

Study of epcoritamab, venetoclax and ibrutinib in treatment‑naïve chronic lymphocytic leukemia patients with TP53 alterations

Registered drugNo placebo

Study of epcoritamab, venetoclax and ibrutinib in treatment‑naïve chronic lymphocytic leukemia patients with TP53 alterations

Registered drugNo placebo

France

Participants:18–64 years · 65+ years
Substances:Epcoritamab
Sponsor:LYSARC

Contact Research Centre

Paroxysmal nocturnal haemoglobinuria

Not yet recruiting

Study of VSA012 Sodium in Paroxysmal Nocturnal Hemoglobinuria Patients Who Are Complement Inhibitor‑Naïve or Have Persistent Anemia on C5 Inhibitor Therapy

InvestigationalNo placebo

Study of VSA012 Sodium in Paroxysmal Nocturnal Hemoglobinuria Patients Who Are Complement Inhibitor‑Naïve or Have Persistent Anemia on C5 Inhibitor Therapy

InvestigationalNo placebo

France

Participants:18–64 years · 65+ years

Contact Research Centre

Obesity+1

Not yet recruiting

Study of Once‑Weekly Eloralintide (LY3841136 Sodium) in Adults with Obesity or Overweight, Type 2 Diabetes, and High Cardiovascular Risk

Investigational

Study of Once‑Weekly Eloralintide (LY3841136 Sodium) in Adults with Obesity or Overweight, Type 2 Diabetes, and High Cardiovascular Risk

Investigational

France

Participants:18–64 years
Substances:LY3841136 sodium
Sponsor:Eli Lilly & Co.

Contact Research Centre

Anaemia+1

Not yet recruiting

Study of Elritercept (TAK‑226) with Ruxolitinib vs Placebo in Patients with Myelofibrosis and Anemia on Ruxolitinib Therapy

Registered drug

Study of Elritercept (TAK‑226) with Ruxolitinib vs Placebo in Patients with Myelofibrosis and Anemia on Ruxolitinib Therapy

Registered drug

France

Participants:18–64 years · 65+ years
Substances:Elritercept
Sponsor:Takeda Development Center Americas Inc.

Contact Research Centre

Other cities in France

The busiest research cities in the country

All 382 cities in France

Clinical research in Poitiers

What the registry says about research in the country

01 Oncology Research

Innovative clinical trials focusing on multiple myeloma, colorectal cancer, and various advanced cancers. Studies are evaluating novel therapeutic combinations and treatment strategies for better patient outcomes.

Advanced Gastric Cancer Treatments
Pancreatic Adenocarcinoma Therapy
Myelodysplastic Syndromes

Several trials are investigating targeted therapies and immunotherapy approaches for various cancer types.

02 Neurological Studies

Research focusing on essential tremor treatments and innovative therapeutic approaches. Clinical trials are evaluating new medications for movement disorders.

Movement Disorders
Neurological Conditions
Early Psychosis Treatment

Studies aim to improve patient quality of life through novel therapeutic interventions.

03 Transplant Medicine

Advanced research in kidney transplantation and post-transplant care, including studies on antibody-mediated rejection prevention and treatment strategies.

Organ Transplantation
Immunosuppression Protocols
Rejection Prevention

Trials focus on improving long-term outcomes for transplant recipients.

04 Critical Care Medicine

Studies evaluating postoperative care and pain management in critical care settings, including innovative approaches to patient comfort and recovery.

Pain Management
Postoperative Care
Patient Comfort Optimization

Research aims to enhance patient comfort and recovery in intensive care settings.

Back to France All countries